SPANX family member N5Genealiases: CT11.10 · SPANX-N5
Q-omics provides the consensus-scored SPANXN5 profile across patient tissues and cancer cell-line models. SPANXN5 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, SPANXN5 is differentially expressed in 3, with the highest sampling consensus in LUSC. Additionally, SPANXN5 RNA expression shows 5,195 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight BLCA, LUSC, and STAD as cancer lineages where SPANXN5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPANXN5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPANXN5 survival associations across molecular data types. SPANXN5 RNA expression shows survival associations in the most cancer types (15), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPANXN5 RNA expression–survival associations across cancer types. High SPANXN5 expression shows unfavorable associations in BLCA, BRCA, LUSC, OV, COAD and ESCA. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for SPANXN5 RNA expression.
This table summarizes SPANXN5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for SPANXN5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPANXN5 shows higher tumor expression in LUSC, HNSC and KIRP. The LUSC box plot shows higher SPANXN5 RNA expression in tumor versus normal tissue (log2 FC = +0.027, t-test p = .005).
This table shows molecular features associated with SPANXN5 in patient tissues and cancer cell lines. In patient samples, SPANXN5 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, SPANXN5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and LARGE_INTESTINE.
